Nebulized amphotericin B combined with intravenous amphotericin B in rats with severe invasive pulmonary aspergillosis.
Nebulized amphotericin B (AMB) combined with intravenous AMB was studied in persistently leukopenic rats with invasive pulmonary aspergillosis. Pulmonary concentrations of AMB after aerosol treatment were substantially higher than after intravenous liposomal AMB. Nebulized liposomal AMB in addition to intravenous AMB resulted in significantly prolonged survival compared to controls.
Ruijgrok
Elisabeth J
EJ
Department of Clinical Pharmacy, Medical Center Rijnmond-Zuid, Olympiaweg 350, 3078 HT Rotterdam, The Netherlands. e.j.ruijgrok@hetnet.nl
Fens
Marcel H A M
MH
Bakker-Woudenberg
Irma A J M
IA
van Etten
Els W M
EW
Vulto
Arnold G
AG
D000666:Amphotericin B / Q000008:administration & dosage* / Q000494:pharmacology; D000818:Animals; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000494:pharmacology; D001228:Aspergillosis / Q000188:drug therapy*; D001232:Aspergillus fumigatus / Q000187:drug effects*; D015415:Biomarkers / Q000378:metabolism; D007275:Injections, Intravenous; D008081:Liposomes; D008172:Lung Diseases, Fungal / Q000188:drug therapy* / Q000382:microbiology; D009330:Nebulizers and Vaporizers / Q000382:microbiology; D051381:Rats; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000935:Antifungal Agents; D015415:Biomarkers; D008081:Liposomes; D000666:Amphotericin B